Adjuvant sunitinib declined by European Medicines Agency committee
The Committee for Medicinal Products for Human Use (CHMP) of [...]
Status of adjuvant therapy for the treatment of kidney cancer
Dr Naomi Haas from Abramson Cancer Centre, Philadelphia, presented an [...]
Pembrolizumab investigated as adjuvant therapy for renal cell carcinoma
Immunotherapy has been a major breakthrough in the treatment of [...]
Adjuvant therapy for renal cell carcinoma
The following article is a good review of the data [...]
Neoadjuvant and adjuvant therapy for renal cell carcinoma: critique, current trials and future directions
The following articles discuss the use of neoadjuvant therapy (drug [...]
Adjuvant therapy for high risk kidney cancer
Dr Umberto Capitanio from the Department of Urology, San Raffaele [...]
Sunitinib approved by the FDA for adjuvant treatment of advanced kidney cancer
The US Food and Drug Administration (FDA) has approved sunitinib [...]
Adjuvant therapy in renal cell carcinoma: a review of the clinical trials to date
The number of drugs available to fight advanced renal cell carcinoma [...]
Adjuvant pazopanib shows no benefit for locally-advanced kidney cancer
Results from the phase 3 PROTECT clinical trial, which compared [...]
A test to gauge recurrence risk for kidney cancer is unable to predict which patients will benefit from adjuvant therapy
An American company called Genomic Health has been collaborating with [...]
